Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin

Prado, Kleber D.; Patzina, Rosely Antunes; Bergamaschi, Denise Pimentel; Focaccia, Roberto

doi:10.1590/s1413-86702008000500004

Cited by 3 publications

(1 citation statement)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, we found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2b (12,5) kD with ribavirin (p=0.000, p<0.05) ( Table 4 ). Similar results have been found in other studies ( 16 , 17 , 18 , 19 ) i.e. there is growing clinical evidence that fibrosis can regress and possibly even resolve in a number of liver diseases.…”

Section: Discussionsupporting

confidence: 91%

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

et al. 2014

View full text Add to dashboard Cite

Background:HCV infection is characterized by a tendency towards chronicity. Acute HCV infection progresses to chronic infection in 70% of cases. Hepatitis C virus infection can cause progressive liver injury and lead to fibrosis and eventually cirrhosis. The degree of histologic fibrosis is an important marker of the stage of the disease. One of current standard treatment for CHC infection is the combination of PEG-IFN α and ribavirin.Objectives:The aim of the study was to investigate the effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver fibrosis in patients with chronic hepatitis C. Also, our aim was to examine whether there was a difference between the genders in the efficacy of these antiviral therapy. Our goal also was to determine effect of the therapy with Peginterferon alfa-2a or alfa-2b plus Ribavirin on evolution of liver steatosis in patients with chronic hepatitis C.Patients and Methods:A retrospective study was made of chronic hepatitis C patients who had been treated from 2005 to April 2014 at the Clinic of Gastroenterohepatology, Clinical Center University of Sarajevo. We reviewed 40 patient medical records to collect demographic, epidemiological and clinical information, as information on liver biopsies that was performed prior to the antiviral therapy and FibroScan® test that was performed after the antiviral therapy. For the processing of data SPSS (Statistical Package for the Social Sciences Program) for Windows, ver. 21.0 statistical software was used. Comparisons between qualitative and quantitative variables were performed using the Student t-test. Mann Whitney U test was used to compare differences in variables such as fibrosis stage and steatosis grade. A value of p<0.05 was considered as statistically significant.Results:After treatment, there was a statistically significant increase in the number of patients with no fibrosis (p<0.05). There was no statistically significant reduction in the number of patients with cirrhosis (F4) (p>0.05). There was significantly higher decrease of fibrosis progression at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction. We found significant association in evolution of fibrosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p< 0.05). We also found significant association in evolution of steatosis after treatment with PEG-IFN α2a (40) kD and PEG-IFNα2a (12,5) kD with ribavirin (p < 0.05). There was statistically significant differences (p<0.05) between genders within fibrosis qualitative evolution.Conclusions:There were significant regression of fibrosis especially at the patients that were in an mild-to-moderate fibrosis (F1/F2/F3), patients that were in advanced stage of fibrosis (F4) at the time of the pre-treatment did not have a statistically significant fibrosis reduction after treatment with PEG-IFN α2a (40) ...

show abstract

Section: Discussionsupporting

confidence: 91%

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

et al. 2014

View full text Add to dashboard Cite

show abstract

Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens

Raziky

Khairy

Fouad

et al. 2018

Journal of Interferon & Cytokine Research

View full text Add to dashboard Cite

Hepatitis C virus (HCV) treatment is aiming to cure and prevent the development, progression of fibrosis, and related complications. Interferon-based therapy was claimed to reduce or even reverse fibrosis. Although direct-acting agents have a better cure rate, we still lack the knowledge of their effect on fibrosis regression. We aim to assess fibrosis regression in direct-acting agents compared with interferon-based treatment regimens in the treatment of chronic HCV patients. The 204 chronic HCV patients were divided into 3 groups; group 1(N = 68) received Peg-IFN and ribavirin, group 2 (N = 69) received sofosbuvir and ribavirin, and group 3 (N = 67) received Peg-IFN, ribavirin, and sofosbuvir. Fibrosis assessment was performed by transient elastography (TE), APRI and FIB 4, in the pretreatment and at least 3 months after end of treatment. Of these, 66.2% of the patients did not show significant fibrosis changes, 6.4% fibrosis progressed, and 27.5% of fibrosis regressed (P < 0.0001) by TE. Similar results were detected in the different treatment regimens with no statistically significant difference between the regimens. Fibrosis regression was detected in 43.3% of cirrhotic patients who achieved sustained virological response (SVR) and only in 27.4% with significant fibrosis. Significant improvement of posttreatment aspartate transaminase, alanine transaminase, and alpha fetoprotein as well as APRI and FIB 4 scores were detected. Fibrosis regression (TE, APRI and FIB 4) was detected with direct-acting agents and interferon-based therapy. Treated patients with significant fibrosis will benefit of fibrosis regression irrespective to their treatment response, whereas fibrosis regression was associated with SVR in cirrhotic patients.

show abstract

Avaliação da progressão da fibrose hepática em adultos coinfectados pelo vírus HIV e da hepatite C por meio de biópsias hepáticas pareadas

Bo¹

View full text Add to dashboard Cite

Histological response study of chronic viral hepatitis C patients treated with interferon alone or combined with ribavirin

Cited by 3 publications

References 35 publications

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

Analysis of Effect of Antiviral Therapy on Regression of Liver Fibrosis in Patient with HCV Infection

Effect of Direct-Acting Agents on Fibrosis Regression in Chronic Hepatitis C Virus Patients' Treatment Compared with Interferon-Containing Regimens

Avaliação da progressão da fibrose hepática em adultos coinfectados pelo vírus HIV e da hepatite C por meio de biópsias hepáticas pareadas

Contact Info

Product

Resources

About